The LPD solution is applied in both the Toronto lung transplant program and in clinical programs around the world [REF].
Dr. Keshavjee's work has demonstrated that immunosuppression related to transplantation leads to an altered expression of the transgene, and immunosuppression will lead to prolonged expression of the transgene.